CLINICAL ROLE -
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
FDA Grants Accelerated Approval for Liso-Cel in Patients With Relapsed or Refractory Follicular Lymphoma
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Key Considerations for Implementing CRISPR/Cas9 Therapy in Health Systems
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
FDA Grants 510(k) Clearance for Rika Plasma Donation System
Acalabrutinib Demonstrates Improvements in PFS in Patients With Previously Untreated MCL